Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials

2015257 citationsReviewgold Open Access

Authors

Xinlin Zhang · Nanjing Drum Tower Hospital

Qingqing Zhu · Jinling Institute of Technology

Li Zhu · Nanjing Drum Tower Hospital

Jianzhou Chen · Nanjing Drum Tower Hospital

Qinhua Chen · Nanjing Drum Tower Hospital

Guannan Li · Nanjing Drum Tower Hospital

Jun Xie ·

Abstract

Evolocumab and alirocumab were safe and well-tolerated from our most-powered analyses. Both antibodies substantially reduced the LDL-C level by over 50 %, increased the HDL-C level, and resulted in favorable changes in other lipids.

Topics & Keywords

Lipoproteins and Cardiovascular Health

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: BMC Medicine

Volume 13, Issue 1, pp. 123-123

DOI: 10.1186/s12916-015-0358-8

Field-Weighted Citation Impact: 37.76